Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors

Published:2004-06-07 Issue:36 Volume:23 Page:6056-6063
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Carlomagno Francesca,Guida Teresa,Anaganti Suresh,Vecchio Giancarlo,Fusco Alfredo,Ryan Anderson J,Billaud Marc,Santoro Massimo

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/1207810.pdf

Reference45 articles.

1. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NC and Goldman JM . (2002). N. Engl. J. Med., 347, 481–487.

2. Asai N, Iwashita T, Matsuyama M and Takahashi M . (1995). Mol. Cell. Biol., 15, 1613–1619.

3. Bartsch DK, Hasse C, Schug C, Barth P, Rothmund M and Hoppner W . (2000). Exp. Clin. Endocrinol. Diabetes, 108, 128–132.

4. Bishop AC, Ubersax JA, Petsch DT, Matheos DP, Gray NS, Blethrow J, Shimizu E, Tsien JZ, Schultz PG, Rose MD, Wood JL, Morgan DO and Shokat KM . (2000). Nature, 407, 395–401.

5. Blencke S, Ullrich A and Daub H . (2003). J. Biol. Chem., 278, 15435–15440.

Cited by 220 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: “Shadows and Fogs”;Cancers;2024-08-19

2. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14

3. Insights into highly selective RET inhibitors in medullary thyroid cancer;Current Opinion in Endocrine and Metabolic Research;2024-06

4. Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations;Journal of Medicinal Chemistry;2024-03-14

5. Rearranged during transfection (RET) inhibitors;Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3